Award - Development of Novel Drug Particles for Inhalational Therapy
Award Notice Posted
- Solicitation number
- HT9425-24-D-0011
- Agency
-
Defense Health Agency
Department of Defense
- Set-aside
- No set-aside
Opportunity facts
- Contract number
- HT9425-24-D-0011 Federal IDV award
- NAICS code
- 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- PSC
- AJ11 General Science And Technology R&D Services; General Science And Technology; Basic Research
- Place of performance
- Frederick, Maryland 21702, United States
Notice details come from SAM.gov. Updated .
About this opportunity
This Award Notice announces the sole source award of a firm fixed price contract to CritiTech Particle Engineering Solutions, LLC for the development of novel drug particles for inhalational therapy. The Defense Health Agency awarded contract HT9425-24-D-0011 to CritiTech Particle Engineering Solutions, LLC for $709,995.75 on September 6, 2024. The award was made sole source due to CritiTech's proprietary Purcision technology, which can produce drug particles in the optimal size range for inhalation without the use of excipients, allowing for high drug loads. This technology will provide the government with a novel and highly advantageous medical countermeasure for the treatment of pulmonary infections that is easily deployable with the Warfighter.
Notice text
This contract was awarded sole source and firm fixed price to CritiTech Particle Engineering Solutions, LLC due to their proprietary technology and ability to meet the government's specific needs to delivery long-lasting antimicrobials to the lungs would provide a novel, highly advantageous medical countermeasure that would be easily deployable with the Warfighter. CritiTech Particle Engineering Solutions, LLC is the sole provider capable of developing novel, super-critical precipitated drug products suitable for inhaled drug delivery for the treatment of pulmonary infections. This vendor has a proprietary technology (Purcision) that relies on supercritical precipitated API to produce particles in the correct size for inhalation (0.5 – 5.0 µm) with very high surface area and no drug excipients, which allows for high drug loads compared to other methods. This vendor is the sole source of LSAM used for oncology programs and has a demonstrated track record as a formulations contract research organization (CRO). No other company found was able to deliver particles that match all the requirements simultaneously.
Awarded contract HT9425-24-D-0011 to CRITITECH PARTICLE ENGINEERING SOLUTIONS, LLC for 709995.75 on 2024-09-06.
Notice history
| Notice | Type | Posted |
|---|---|---|
| Award - Development of Novel Drug Particles for Inhalational Therapy | Award Notice | |
| This notice | Award Notice | |
| Development of Novel Drug Particles for Inhalational Therapy | Special Notice |
On GovTribe
Work this opportunity
- Track it in your pipeline
- Find teaming partners
- Similar opportunities
- Ask GovTribe AI about this opportunity